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Background. After failure of first-line antiretroviral therapy (ART) in the public sector, delayed 2 
or missed second-line ART switch is linked with poor outcomes in patients with advanced HIV.  3 
 4 
Setting: We investigated delayed or missed second-line ART switch following confirmed 5 
virologic failure in the largest private sector HIV cohort in Africa. 6 
 7 
Methods. We included HIV-infected adults with confirmed virologic failure after six months of 8 
non-nucleoside reverse-transcriptase inhibitor-based ART. We estimated the effect of timing of 9 
switch on the hazard of death using inverse probability of treatment weighting of marginal 10 
structural models. We adjusted for time-dependent confounding of CD4 count, viral load, and 11 
visit frequency. 12 
 13 
Results. 5748 patients (53% female) with confirmed virologic failure met inclusion criteria; the 14 
median age was 40 (interquartile range [IQR]: 35 - 47), advanced HIV was present in 48% and 15 
the prior duration of NNRTI-based ART was 1083 days (IQR: 665-1770). Median time to 16 
confirmation of virologic failure and to second-line switch was 196 (IQR: 136-316) and 220 days 17 
(IQR: 65-542), respectively. Switching to second-line ART after confirmed failure compared to 18 
remaining on first-line ART reduced risk of subsequent death [aHR: 0.47 (95% CI: 0.36-0.63)]. 19 
Compared to patients who experienced delayed switch, those switched immediately had a lower 20 
risk of death, regardless of CD4 cell count. 21 
 22 
 4 
Conclusions. Delayed or missed switch to second-line ART after confirmed first-line ART 23 
failure is common in the South African private sector and associated with mortality. Novel 24 
interventions to minimize switch delay should be tested and not limited to those with advanced 25 
disease at treatment failure. 26 
 27 
 28 
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 5 
Introduction 31 
With the expansion of routine VL monitoring and earlier identification of antiretroviral therapy (ART) 32 
failure, the demand for second-line ART in sub-Saharan Africa has increased. By 2020 the number of 33 
patients who will require second-line ART is estimated to be 500,000 to 3 million.1 Unfortunately in 34 
sub-Saharan Africa the delay between first-line ART virologic failure – HIV viral load >1000 copies/mL 35 
for two consecutive measurements – and the initiation of effective second-line ART can be prolonged.2,3   36 
 37 
Significant delay before switch to second-line ART may result from multiple factors including clinician 38 
reluctance to switch when prior adherence is uncertain, concerns about the increased toxicity of second-39 
line ART and because patients with virologic failure are more likely to cycle in and out of care.4,5 Also 40 
contributing to switch delay are algorithms embedded in World Health Organization (WHO) and other 41 
HIV treatment guidelines. For example, national treatment guidelines in South Africa recommend a 42 
routine two month delay prior to second-line switch in order to accommodate additional adherence 43 
support and laboratory confirmation of virologic failure.6,7 Switch delay has important clinical 44 
consequences including placing patients with ongoing virologic failure at increased risk for OI and 45 
mortality as reported in Ugandan and South African public sector.8,9,10,11,12,13,14,19  46 
 47 
One reason delayed switch has proven hazardous is because, at the time of virologic failure, advanced 48 
HIV infection is already present in about half of patients. However, not all patients in high-prevalence 49 
regions are managed in the public sector. Patients in the private sector account for 8.5% of persons with 50 
HIV in South Africa. These patients experience a higher doctor to patient ratio and shorter waiting times 51 
with better access to care, including clinicians, pharmacies and phlebotomy facilities for laboratory 52 
 6 
monitoring. However, whether these factors translate into improved management of first-line treatment 53 
failure is uncertain. 54 
 55 
We investigated the prevalence and consequences of delayed and missed switch following confirmed 56 
virologic failure among patients receiving first-line ART in South Africa within the Aid for AIDS cohort 57 
– a private sector managed care program using the same switch threshold (two consecutive plasma viral 58 
loads >1000 c/mL) as the public sector – with the hypothesis that delayed or missed switch is also 59 
common in the private sector and associated with increased patient mortality, particularly in patients 60 
with advanced HIV disease.15 61 
 62 
Methods 63 
Ethics Statement 64 
The study was approved by the Human Research Ethics Committee of the University of Cape 65 
Town (HREC R007/2015) and the Institutional Review Board of the Los Angeles Biomedical 66 
Research Institute (31123-01).  67 
 68 
Study Design and Setting 69 
In the absence of a randomised trial, we designed a “target trial” from observational data and 70 
applied causal inference methods to adjust for time-dependent confounding affected by prior 71 
treatment decisions with two aims.16,17,18 The first was to estimate among patients with first-line 72 
ART virologic failure the impact of a switch to second-line treatment, compared to not switching, 73 
on subsequent mortality, defining time zero as the time of confirmed virological failure (time of 74 
 7 
second viral load > 1000 c/mL). The second was to estimate the impact on mortality of a delay in 75 
switch to second-line ART.  76 
 77 
We identified adult patients who experienced confirmed virologic failure on first-line ART 78 
within the AfA cohort, regardless of whether or not a second-line ART regimen was initiated. 79 
AfA is a unique cohort of HIV-infected patients in the private sector in South Africa; AfA 80 
collects demographic, clinical, medication and laboratory data relating to patients receiving HIV 81 
care through this scheme. AfA treatment protocols conform to the WHO HIV treatment 82 
guidelines with first-line ART consisting of two nucleoside reverse-transcriptase inhibitors 83 
(NRTIs) plus one non-nucleoside reverse-transcriptase inhibitors (NNRTI) and second-line ART 84 
consisting of two NRTIs plus one boosted protease inhibitor (PI). The first-line ART initiation 85 
threshold changed over time reflecting the evolution of WHO and South African 86 
recommendations. Virologic monitoring was recommended at 6 month intervals until 2015, and 87 
subsequently every 12 months. 88 
 89 
The study population included adult patients (over 18 years of age) who received first-line ART 90 
treatment for at least 6 months and who failed first-line ART between 1st January 2012 and 91 
database closure on 31st August 2017. Patients were excluded if (1) initial ART did not consist of 92 
a standard first-line regimen (2 NRTIs + 1 NNRTI), or (2) if virologic failure occurred less than 93 




First-line virologic failure was defined as two consecutive VL measures greater than 1000 RNA 97 
copies per mL at least 4 weeks apart after a minimum of 6 months of first-line NNRTI-based 98 
ART. We defined advanced HIV as a CD4 <200 cells/uL at the time of first-line ART virologic 99 
failure and defined second-line as a regimen that replaced a first-line regimen and contained at a 100 
ritonavir-boosted protease inhibitor (bPI).  101 
 102 
Statistical analysis 103 
We censored patients when they were lost to follow-up (LTFU) which we defined as 9 months 104 
without visit after a patient has last been seen at a health care facility. Thus, follow-up ended at 105 
time of LTFU, which is last visit plus 9 months. Censoring also occurred due to patients leaving 106 
the scheme and at time of database closure.  107 
 108 
To estimate the effect of second-line switch versus no switch, we applied inverse probability of 109 
treatment weighting (IPTW) of marginal structural models.20 Censoring weights were also 110 
applied to adjust for bias from LTFU, leaving the scheme and administrative censoring, Both 111 
treatment and censoring weighting models included baseline covariates in the denominator and 112 
included baseline and time dependent covariates in the numerator as described previously.17,19 113 
Measured baseline characteristics at time of confirmed virologic failure were age, sex, highest 114 
and lowest CD4 count prior to failure, highest and lowest log VL measure prior to failure, a 115 
binary indicator of VL suppression prior to failure, WHO clinical stage and year of ART 116 
initiation. Time-varying confounders that were assumed to be affected by prior treatment 117 
decisions included CD4 count, VL and treatment frequency measured as number of visits within 118 
 9 
the past 6 months. Stabilized weights were estimated using pooled logistic models, truncated at 119 
the 99th percentile and applied within a marginal structural pooled logistic model.   120 
 121 
To estimate the impact of the timing of the switch on mortality, we defined five switching 122 
strategies as follows; no switch, less than 30 days from VL failure to switch, greater than or 123 
equal to 30 days and less than 60 days from VL failure to switch, greater than or equal to 60 days 124 
and less than 90 days from VL failure to switch, and greater than or equal to 90 days from VL 125 
failure to switch. The dataset was replicated five times, each replicate corresponding to one of 126 
the five strategies. Patient time was censored at the time point that the patient ceased to adhere to 127 
the corresponding strategy. The probabilities for the numerator and denominator of the treatment 128 
and censoring weights were estimated using pooled logistic models, which included the above-129 
mentioned variables and were truncated at the 99th percentile. To create the weights, probabilities 130 
from treatment and censoring denominator and numerator models were assigned to each person-131 
time point, and cumulative probabilities were calculated overtime. The weights applied in the 132 
marginal structural outcome model were calculated by dividing numerator by denominator 133 
cumulative probabilities, and multiplying treatment and censoring weight together. See Rohr et. 134 
al. and Bell-Gorrod et al for more details of the method.10,19     135 
 136 
Results 137 
Study Population 138 
We identified 5748 patients (53% female) with confirmed first-line ART virologic failure 139 
eligible for study inclusion.  The median age was 40 (interquartile range (IQR): 35 - 47) and the 140 
median prior duration of first-line NNRTI-based ART was 35.6 months (IQR: 21.9-58.2). At the 141 
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time of confirmed virologic failure the median CD4 cell count was 208 cells/uL and advanced 142 
HIV (CD4 cell count < 200 cells/uL) was present in 48%. The median time between initial viral 143 
load >1000 copies/mL and confirmation of virologic failure was 6.4 months (IQR: 4.5-10.4). 144 
Additional patient characteristics are shown in Table 1. 145 
  146 
Second-Line ART Switch 147 
At 6, 12, and 24 months after confirmed virologic failure the cumulative number of cases 148 
(proportion) of second-line switch was 964 (17%), 1343 (23%), and 1590 (28%), respectively. 149 
Overall, 1768 (31%) of 5748 patients with confirmed virologic failure were switched. The 150 
median time from confirmation of virologic failure to second-line switch was 12.8 months (IQR: 151 
7.6-21.8). We found that compared to men with confirmed virologic failure women with 152 
confirmed failure were more likely to be switched (OR 1.18, 95% CI=1.07-1.31). Moreover, 153 
patients who had elevated viral loads and low CD4 counts at their last visit, and patients with 154 
many follow-up visits, were also more likely to be switched (Table 2).For example, compared to 155 
patients with a CD4 of >200 cells/uL, the odds of switch was increased in patients with a CD4 156 
cell count <200 cells/uL for a given follow-up time point (OR 1.60, 95% CI= 1.32-1.95).  There 157 
is greater statistical significance of the ORs on the time dependent variables than the baseline 158 
variables, indicating that decisions to switch were more strongly based on the health of the 159 
patient at the time of switch than health at the time of confirmed failure. The time delay between 160 
first elevated viral load and confirmed failure also has predictive power on the probability of 161 
switch. The probability of switch for patients with at least 60 days and less than 120 days 162 
between first elevated viral load and confirmed failure is greater than the probability of switch 163 
for those with less than 60 days between these viral load measures (OR 1.42, 95% CI= 1.11-164 
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1.81). Conversely, the probability of switch for patients with more than a 360 day gap between 165 
first elevated viral load and confirmed failure is lower than for those with less than 60 days 166 
between measures (OR 0.75, 95% CI= 0.58-0.96). 167 
 168 
Overall, 3980 patients (69%) did not switch to second-line ART after confirmed virologic failure. 169 
In this group, only 491 (12%) were observed to achieve virologic suppression (<200 RNA 170 
copies/ml) without switch within 12 months of confirmed failure, 3489 (88%) did not achieve 171 
suppression within 12 months of confirmed failure, 172 (4%) were observed to achieve virologic 172 
suppression after 12 months and before database closure and 155 (4%) did not have an additional 173 
VL measurement beyond 30 days after confirmed virologic failure. 174 
 175 
Mortality 176 
Overall, 421 (7%) of 5748 patients died after confirmed first-line ART virologic failure. Among 177 
those who died, the median time from confirmed failure to death was 7.2 months (interquartile 178 
range (IQR): 2.1-18.2). Mortality was evaluated according to CD4 cell count at failure. The 179 
majority of mortality after failure was observed among patients with advanced HIV at failure, 180 
with 330 (78%) of 421 deaths in this subgroup.  Relatively little mortality was observed in 181 
patients with a CD4 cell count of >350 cells/uL at failure, with 32 (8%) of 421 deaths in this 182 
subgroup.   183 
 184 
Switching to second-line ART after confirmed virologic failure compared to remaining on first-185 
line ART reduced the risk of subsequent death [aHR: 0.47 (95% CI: 0.36-0.63)]. Among patients 186 
with advanced HIV at failure, a switch to second-line ART also reduced the risk of death [aHR: 187 
 12 
0.40 (95% CI: 0. 29-0.56)]. The impact of second-line switch on mortality was further 188 
investigated according to timing of switch. Compared to patients who experienced delayed 189 
switch after failure, those switched immediately had a lower risk of death, regardless of CD4 cell 190 
count. The hazard of mortality was lowest in those that switched within 30 days which, 191 
compared to those that did not switch, was 0.11 (95% CI: 0.09-0.14). Slightly more pronounced 192 
results were found for the subgroup with advanced HIV at failure. Figure 1 shows results for 193 
each of the delay categories in our analysis. 194 
 195 
It was examined whether the prevalence of advanced HIV at the time of confirmed virologic 196 
failure has declined since 2012. The proportion with advanced disease in 2012 was 1118 (50% 197 
with advanced HIV) of 2233, 2013: 368 (53%) of 689, 2014: 307 (45%) of 677, 2015: 319 (46%) 198 
of 688, 2016: 582 (46%) of 1263, and 2017; 85 (43%) of 198 (p value for time trend= 0.041). 199 
These proportions were consistent with a small decline in advanced HIV at failure since 2012.  200 
 201 
Discussions 202 
Delayed or missed switch to second-line ART after virological failure increases mortality in 203 
patients with HIV infection, including in the South African private sector. In the private sector, 204 
40% of patients with confirmed virologic failure during first-line ART had advanced HIV 205 
disease, yet delayed (and missed) switch to second-line ART was very common. 206 
 207 
The median time from first-line ART virologic failure to confirmation of viremia in this private 208 
sector cohort was 6.4 months, and the median time before second-line ART switch in patients 209 
with persistent failure was 12.8 months. A large group of patients who appeared eligible for 210 
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second-line ART were not switched at all. The majority of mortality after virologic failure (78% 211 
of deaths) was observed among patients with advanced HIV with 78% of deaths in this subgroup. 212 
However, a reduction in mortality was observed in all patients with virologic failure when 213 
second-line ART switch occurred; patients with the most rapid switch after confirmed failure 214 
experienced the lowest hazard of death both in the overall cohort and in the subgroup with 215 
advanced HIV disease. This suggests that broad efforts to more rapidly identify with ART failure 216 
in clinics in South Africa and, if necessary, to switch them to active second-line ART may avert 217 
deaths. 218 
 219 
Switch delay is multifactorial but a major contributor in the South African private sector is a 220 
prolonged time-period prior to confirmation of virologic failure. Significant lags before 221 
confirmatory VL testing have also been reported in the public sector in southern Africa.20 This 222 
lengthy delay complicates the identification and management of patients with ongoing treatment 223 
failure and has been the subject of quality improvement interventions, an example of which has 224 
been the introduction of VL “champions” in KwaZulu-Natal, South Africa.4 Another proposed 225 
approach to shorten switch delay after virologic failure is to reduce the second-line switch 226 
threshold from two elevated VL measurements, to a single elevated VL above 1000 copies/mL. 227 
Under a reduced switch threshold approach, which could be applied generally or targeted at 228 
high-risk patients, a switch would take place immediately after the first elevated VL. Under such 229 
an algorithm, instead of delaying switch for adherence training, patients triaged to rapid switch 230 
would receive enhanced adherence simultaneous to or shortly after the switch takes place. This 231 
strategy was modelled in a recent publication which demonstrated that by reducing second-line 232 
switch delay, approximately 10 ,215 deaths could be averted annually in a country the size of 233 
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South Africa.11 Another tool that could potentially reduce switch delay is the wider introduction 234 
of point-of-care viral load testing. Although not yet shown in a clinical trial, point-of-care viral 235 
load monitoring could provide earlier information regarding the need to switch (or not) at the 236 
time of the second (confirmatory) viral load measurement allowing for more rapid treatment 237 
decisions. 238 
 239 
When outcomes among patients with virologic failure in the Aid for AIDS (AfA) cohort are 240 
compared to outcomes in patients with virologic failure in the largest public sector cohort 241 
reported from South Africa, some differences are apparent.10 Notably, compared to patients 242 
described by Rohr et. al. in the South African public sector, in whom the median time to 243 
confirmation of virologic failure and time to switch was 3.4 months and ~6 months, respectively, 244 
patients in the private AfA cohort experienced a longer time to confirmation of failure and longer 245 
time to switch of 6.4 months and 12.8 months, respectively. Delayed identification of treatment 246 
failure and delayed switch may be – compared to the public sector – more common in the South 247 
African private sector. A possible reason for the longer time to second-line switch we observed 248 
could be explained by delays incurred by the treating clinicians with varying experience in the 249 
management of patients with virologic failure.  250 
 251 
However, in important respects, published patient outcomes in the public and private cohorts are 252 
similar. First, in both cohorts it is evident that a significant proportion of patients with confirmed 253 
virologic failure were never switched to second-line ART. Rohr et. al. found that 37% of patients 254 
with confirmed failure never switched to second-line ART and they describe that, following 255 
confirmed failure without switch, that only 28% failing to switch had evidence of virologic 256 
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suppression. In the AfA private cohort, 69% did not switch to second-line ART after confirmed 257 
virologic failure and only 12% of this patient group subsequently had evidence of virologic 258 
suppression without switch. Second, in public and private cohorts it was observed that – in the 259 
absence of switch after virologic failure – rates of loss to follow-up were high. For example, in 260 
the AfA cohort, 42% of patients not switched only had one recorded visit after virologic failure, 261 
compared to 12% of patients who switched to second-line ART. In both sectors, virologic failure 262 
may be an important early warning sign of potential loss to follow-up, highlighting the 263 
importance of virologic failure as a potentially critical event in the HIV care continuum.  Third, 264 
in line results from public settings, we found that predictors of second-line switch include a 265 
higher viral load, a CD4 count below 200 cells/microL and increased clinic visit frequency.21,22 266 
The latter may relate to engagement in care and clinicians’ perception of adherence, and suggests 267 
that switch decisions may not be based purely on guideline algorithms. We also found that 268 
female patients were more likely to be switched than males. Although the mechanism by which 269 
gender affects treatment decisions is unclear, the finding suggests an additional gender-related 270 
differences in HIV management and outcomes in southern Africa.23 271 
 272 
Our study has several strengths. This cohort study represents patients cared for within private 273 
practice settings in South Africa and as a result provides novel evidence that delayed 274 
identification and management of first-line ART virologic failure is not strictly a public sector 275 
issue of limited resources or overwhelming patient numbers.4 Our sample size was very large, 276 
with more than 5000 patients with confirmed virologic failure included given us considerable 277 
power to look at critical subgroups, including patients with advanced disease. Another strength 278 
of our study is the use of marginal structural modelling; this allowed us to adjust for potentially 279 
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confounding variables – namely, CD4 cell count, VL and treatment frequency – that change over 280 
time and are affected by prior treatment decisions. Several potential limitations should be 281 
considered. Ours was a cohort study and the potential for unmeasured confounding exists. For 282 
example, unmeasured factors such as treatment adherence could potentially affect both the 283 
likelihood of switch to second-line ART and the likelihood of mortality after treatment failure. 284 
Unfortunately we did not have access to direct measures of adherence. Further, we only included 285 
patients who had confirmed virologic failure with two VL measurements > 1000 copies/ml. By 286 
definition, our study excludes patients who had a single VL indicating initial virologic failure but 287 
were subsequently lost to follow-up or died. This may be a substantial patient subgroup with 288 
particularly poor outcomes but is a difficult group to study as they are – by definition – out of 289 
care and often with no recorded outcomes.  290 
 291 
Despite better access to care and monitoring, delayed or missed switch to second-line ART after 292 
first-line ART virologic failure is common in the South African private sector. Our findings 293 
suggest the need to both strengthen the management of virologic failure and to test novel 294 
interventions to reduce switch delay to less than 30 days in patients with first-line regimen 295 
failure. Although these could be targeted at patients with advanced HIV, who continue to make 296 
up 40-50% of patients in South Africa with treatment failure, we found benefit of rapid switch in 297 
all patients with treatment failure. Another approach worth considering, based on a modelling 298 
exercise showing potential net public health benefit, is reducing the second-line ART switch 299 
threshold to a single VL > 1000 c/ml.11 This would, albeit at the cost of some unnecessary 300 
switching, hasten switch tempo considerable and, based on modelling, save thousands of lives 301 
otherwise lost resulting from unnecessary delays. Additional research in this domain will be 302 
 17 
critical – as virologic monitoring is expanded and more patients with virologic failure are 303 
identified – in strengthening the management of ART virologic failure and optimizing long-term 304 
on-treatment patient survival. 305 
 306 
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CD4 <200 at failure 
(N=2779) 
 
CD4 >200 at failure 
(N=2958) 







Female gender [number,  %] 3038 (53) 1295 (47) 1734 (59) 
Achieved VL suppression prior to failure, [number, %] 2687 (47) 1028 (37) 1659 (56) 







CD4 count (cells/uL) at failure [number, %]    
 0-99 1419 (25) 1419 (51) - 
 100-199 1360 (24) 1360 (49) - 
 200-349 1676 (29) - 1676 (56) 
 350-499 730 (13) - 730 (25) 
 >500 563 (10) - 563 (19) 







HIV-1 RNA (c/ml) at failure [number, %]    
<10,000 1,745 (30) 429 (16) 1316 (44) 
10,000-99,999 2,523 (44) 1202 (43) 1321 (44) 
 >100,000 
1,480 (26) 1148 (41) 332 (11) 
Time from confirmed failure to last contact [median, IQR] 368 (214-824) 326 (196-593) 442 (244-993) 
Type of last contact [number, %]    
 Administrative censoring 1713 (30) 600 (25) 1113 (33) 
 Lost to follow-up 3614 (63) 1446 (61) 2168 (64) 
 Death 421 (7) 338 (14) 83 (2) 
Time to loss to follow-up [median, IQR] 309 (206-587) 279 (186-427) 331 (210-757) 
Table 2: Predictors of switch from first-line to second-line ART  411 
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  Odds ratio (OR) of switch to second-line ART 
  




  CD4 cell count, per mm3 <200 1.60 0.000 (1.32-1.95) 
  RNA, copies/ml (reference-category >=0 and <250) 
     >=250 and <500 2.00 0.043 (1.02-3.90) 
     >=500 and <1000 1.28 0.548 (0.57-2.88) 
     >=1000 and <10000 6.24 0.000 (4.26-9.14) 
     >=10000 and <100000 10.61 0.000 (7.15-15.75) 
     >=100000 12.89 0.000 (8.40-19.79) 
  Time-CD4 interaction 1.00 0.000 (1.00-1.00) 
  Time-RNA interaction 0.99 0.000 (0.99-0.99) 
  Number of visits within the past 6 months 1.05 0.000 (1.04-1.06) 
Baseline 
  CD4 cell count, per mm3 <200 0.90 0.263 (0.74-1.09) 
  RNA, copies/ml (reference-category >=1000 and <5000) 
     >=5000 and <10000 1.24 0.031 (1.02-1.51) 
     >=10000 and <50000 0.98 0.827 (0.80-1.19) 
     >=50000 and <100000 0.96 0.691 (0.77-1.19) 
     >=100000 0.88 0.290 (0.70-1.11) 
Time from first elevated VL to confirmed failure (reference-category <60) 
     >=60 and <120 days 1.42 0.005 (1.11-1.81) 
     >=120 and <240 days 1.04 0.699 (0.83-1.32) 
     >=240 and <360 days 0.83 0.142 (0.65-1.07) 
     <360 days 0.75 0.023 (0.58-0.96) 
  Pre-failure VL suppression 1.04 0.876 (0.64-1.70) 
  Age 1.00 0.269 (1.00-1.01) 
  Female gender  1.18 0.001 (1.07-1.31) 
This analysis was performed using a logistic model with a binary switch dependent variable, and adjusted for follow-up time using restricted cubic splines.  412 
Other controls include pre-failure highest and pre-failure lowest CD4 and RNA, binary indicator of year of failure. This model was used to estimate the denominator probabilities for the switching 413 
weights, which were used to adjust for time-dependent confounding in the survival analysis shown in figure 1. The time-dependent variables change over time from baseline to switch. The time-414 
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dependent variables have larger ORs and tend to be more statistically significant than the baseline variables, because the decision to switch depends more heavily on the patient characteristics at the 415 
time of switch. ORs for RNA categories should be interpreted relative to the reference-category, where each reference category represents an OR=1.00. 416 
Figure 1. Hazard rations for death in patients with confirmed virologic failure by timing of second-line ART switch  417 
 418 
*Adjusted for time-dependent confounding of CD4 count, VL, and visit frequency. 419 
